» Articles » PMID: 31206626

Pathogenic and Likely Pathogenic Variants in PALB2, CHEK2, and Other Known Breast Cancer Susceptibility Genes Among 1054 BRCA-negative Hispanics with Breast Cancer

Abstract

Background: Breast cancer (BC) is the most common cancer and related cause of mortality among Hispanics, yet susceptibility has been understudied. BRCA1 and BRCA2 (BRCA) mutations explain less than one-half of hereditary BC, and the proportion associated with other BC susceptibility genes is unknown.

Methods: Germline DNA from 1054 BRCA-mutation-negative Hispanic women with hereditary BC (BC diagnosed at age <51 years, bilateral BC, breast and ovarian cancer, or BC diagnosed at ages 51-70 years with ≥2 first-degree or second-degree relatives who had BC diagnosed at age <70 years), 312 local controls, and 887 multiethnic cohort controls was sequenced and analyzed for 12 known and suspected, high-penetrance and moderate-penetrance cancer susceptibility genes (ataxia telangiectasia mutated [ATM], breast cancer 1 interacting protein C-terminal helicase 1 [BRIP1], cadherin 1 [CDH1], checkpoint kinase 2 [CHEK2], nibrin [NBN], neurofibromatosis type 1 [NF1], partner and localizer of BRCA2 [PALB2], phosphatase and tensin homolog [PTEN], RAD51 paralog 3 [RAD51C], RAD51D, serine/threonine kinase 11 [STK11], and TP53).

Results: Forty-nine (4.6%) pathogenic or likely pathogenic variants (PVs) in 47 of 1054 participants (4.5%), including 21 truncating frameshift, 20 missense, 5 nonsense, and 4 splice variants, were identified in CHEK2 (n = 20), PALB2 (n = 18), ATM (n = 5), TP53 (n = 3), BRIP1 (n = 2), and CDH1 and NF1 (both n = 1) and none were identified in NBN, PTEN, STK11, RAD51C, or RAD51D. Nine participants carried the PALB2 c.2167_2168del PV (0.85%), and 14 carried the CHEK2 c.707T>C PV (1.32%).

Conclusions: Of 1054 BRCA-negative, high-risk Hispanic women, 4.5% carried a PV in a cancer susceptibility gene, increasing understanding of hereditary BC in this population. Recurrent PVs in PALB2 and CHEK2 represented 47% (23 of 49) of the total, suggesting a founder effect. Accurate classification of variants was enabled by carefully controlling for ancestry and the increased identification of at-risk Hispanics for screening and prevention.

Citing Articles

Los olvidados: Non-BRCA variants associated with Hereditary breast cancer in Mexican population.

Aguilar D, Garza-Rodriguez M, Muniz-Garza C, Nunez F, Villarreal-Garza C, Vidal-Gutierrez O Breast Cancer Res. 2025; 27(1):7.

PMID: 39815370 PMC: 11737022. DOI: 10.1186/s13058-024-01957-9.


Contribution of large genomic rearrangements in BRCA1/2 genes and CHEK2 1100delC allele variant to the development of breast/ovarian cancer in Argentinian population.

Berlanga L, Lotersztein V, Aranda E, Cerretini R Breast Cancer Res Treat. 2024; .

PMID: 39704897 DOI: 10.1007/s10549-024-07576-4.


Untapped Potential of Poly(ADP-Ribose) Polymerase Inhibitors: Lessons Learned From the Real-World Clinical Homologous Recombination Repair Mutation Testing.

Lebedeva A, Veselovsky E, Kavun A, Belova E, Grigoreva T, Orlov P World J Oncol. 2024; 15(4):562-578.

PMID: 38993246 PMC: 11236374. DOI: 10.14740/wjon1820.


Spectrum and characteristics of germline PALB2 pathogenic variants in 1556 early-onset breast cancer patients in China.

Li J, He P, Cai Q, Chen L, Wang Y, Cai W J Cancer Res Clin Oncol. 2024; 150(6):322.

PMID: 38914840 PMC: 11196361. DOI: 10.1007/s00432-024-05758-7.


Variants Extend the Mutational Profile of Hungarian Patients with Breast and Ovarian Cancer.

Butz H, Nagy P, Papp J, Bozsik A, Grolmusz V, Pocza T Cancers (Basel). 2023; 15(17).

PMID: 37686625 PMC: 10487218. DOI: 10.3390/cancers15174350.


References
1.
Chavarri-Guerra Y, Blazer K, Weitzel J . Genetic Cancer Risk Assessment for Breast Cancer in Latin America. Rev Invest Clin. 2017; 69(2):94-102. PMC: 5658001. DOI: 10.24875/ric.17002195. View

2.
Wall J, Jiang R, Gignoux C, Chen G, Eng C, Huntsman S . Genetic variation in Native Americans, inferred from Latino SNP and resequencing data. Mol Biol Evol. 2011; 28(8):2231-7. PMC: 3144384. DOI: 10.1093/molbev/msr049. View

3.
Venkitaraman A . Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell. 2002; 108(2):171-82. DOI: 10.1016/s0092-8674(02)00615-3. View

4.
Weitzel J, Lagos V, Blazer K, Nelson R, Ricker C, Herzog J . Prevalence of BRCA mutations and founder effect in high-risk Hispanic families. Cancer Epidemiol Biomarkers Prev. 2005; 14(7):1666-71. DOI: 10.1158/1055-9965.EPI-05-0072. View

5.
Walsh T, Casadei S, Lee M, Pennil C, Nord A, Thornton A . Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A. 2011; 108(44):18032-7. PMC: 3207658. DOI: 10.1073/pnas.1115052108. View